國家衛生研究院 NHRI:Item 3990099045/4540
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 857807      線上人數 : 830
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/4540


    題名: Experience with ifosfamide and etoposide combination chemotherapy in extensive-disease small-cell lung cancer
    其他題名: 使用Ifosfamide和Etoposide治療廣佈期小細胞肺癌的經驗
    作者: Wu, M;Perng, R;Chen, Y;Liu, J;Yang, S;Whang-Peng, J
    貢獻者: National Institute of Cancer Research
    摘要: Background. Ifosfamide, an isomeric analogue of cyclophosphamide, has significant activity against many human tumors including lung cancer, testicular cancer, lymphoma and sarcoma, and may be superior to its analogue. Herein, we report our preliminary experience using ifosfamide and etoposide (IE) combination chemotherapy in previously untreated patients with extensive-disease (ED) small-cell lung cancer (SCLC). Methods. Patients with histologically or cytologically confirmed SCLC, measurable or assessable ED, no previous chemotherapy or thoracic irradiation, younger than 70 years of age, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0- 3, and adequate marrow, liver, and renal functions were eligible for treatment which consisted of ifosfamide 2.0 g/m<sup>2</sup>/d given intravenously (IV) for 3 days with mesna 400 mg/m<sup>2</sup>/dose IV administered 0, 4, and 8 hours after the daily administration of ifosfarnide, and etoposide 80 mg/m<sup>2</sup>/d IV given for 3 days in every 4 weeks for a maximum of 6 cycles. Results. Between January 1994 and February 1995, 10 patients were enrolled into the treatment. All were men with a mean age of 63 ? 6 years. Five patients had an ECOG PS of 0 or 1, 4 patients of 2, and 1 patient of 3. A total of 45 cycles of IE were given. The mean number of cycles per patient was 4.5 ? 2.1. Six patients completed 6 courses of therapy. Thirty-two of 45 cycles (71%) of IE were given at full doses, while the remaining 13 cycles (29%) were given at 75% of doses. Nine patients were assessable for response. Eight patients had a partial remission and one patient had stable disease. The overall response rate was 89%. The median survival was 8 months (range, 0 to 23 months) and the median failure-free survival duration was 5.5 months (range, 0 to 18 months). The 1- and 2-year survival rates were 30% and 0%, respectively. Myelotoxicity was the most important toxicity, particularly neutropenia, while thrombocytopenia and anemia were mild. Five of 10 patients (50%) experienced grade 4 neutropenia, which occurred in 2 patients during the first course of IE and resulted in one patient death from early sepsis. Other nonhematologic toxicities were mild. Conclusions. Our preliminary experience demonstrates that ifosfamide is an active drug against SCLC and combination chemotherapy with IE results in similar response rate and median survival, but probably higher myelotoxicity than reported studies in patients with ED SCLC.
    日期: 1997
    關聯: Chinese Medical Journal (Taipei). 1997;60(2):67-73.
    Link to: http://www.ncbi.nlm.nih.gov/pubmed/9360330
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0030865350
    顯示於類別:[劉敏(1996-2007)] 期刊論文
    [彭汪嘉康(1996-2007)] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    SCP0030865350.pdf1924KbAdobe PDF513檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋